SCHEMBL21288902

SCHEMBL21288902

COc1ccc(CN(C)C(C)(C)CCC=O)cc1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ APLNR P35414 2/20 0.43
▸ ALDH1A1 P00352 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ PYCR1 P32322 1/20 0.41
▸ ACHE P22303 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ POLB P06746 1/20 0.39
▸ TSPO P30536 1/20 0.39
▸ BCL2A1 Q16548 2/20 0.39
▸ TRPM8 Q7Z2W7 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.37
▸ AOC3 Q16853 1/20 0.37
▸ ACLY P53396 1/20 0.37
▸ BCHE P06276 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15471256 0.76 PYCR1 (0.51) APLNRALDH1A1HTTSMN1; SMN2PYCR1
SCHEMBL17275883 0.74 SMN1; SMN2 (0.51) APLNRALDH1A1HTTSMN1; SMN2PYCR1
SCHEMBL21063311 0.72 ALDH1A1 (0.41) ALDH1A1HTTSMN1; SMN2ACHEMEN1
SCHEMBL6826320 0.71 ALDH1A1 (0.42) ALDH1A1MEN1KMT2ATDP1AOC3
SCHEMBL11791442 0.71 PYCR1 (0.47) APLNRALDH1A1HTTSMN1; SMN2PYCR1
SCHEMBL13062564 0.71 APLNR (0.53) APLNRALDH1A1HTTSMN1; SMN2PYCR1
SCHEMBL911097 0.70 TAAR1 (0.55) ALDH1A1HTTSMN1; SMN2AOC3
SCHEMBL25279680 0.69 APLNR (0.59) APLNR
SCHEMBL15094004 0.69 APLNR (0.59) APLNRALDH1A1HTTSMN1; SMN2PYCR1
SCHEMBL9081717 0.69 APLNR (0.55) APLNRALDH1A1HTTSMN1; SMN2PYCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3752510-B1 MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF, THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS, AND PROCESS FOR MAKING THEM VERTEX PHARMA (US) 2022-12-07 — — EP disclosed
WO-2019161078-A1 MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF, THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS, AND PROCESS FOR MAKING THEM VERTEX PHARMACEUTICALS INCORPORATED (US) 2019-08-22 — — WO disclosed
Send feedback